TIME-POINT: TANESPIMYCIN IN MYELOMA EVALUATION: PERFORMANCE OF HSP 90 INHIBITOR AS INITIAL THERAPY Trademark Information

Trademark by Bristol-Myers Squibb Company

Medical and scientific research, namely, conducting clinical trials and clinical studies relating to pharmaceutical preparations for human use

Classification Information

Intent to Use Trademark - Applicant has not submitted proof of use in commerce the the USPTO.

Primary Class: Class Details:
Class (042)
Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
First Use Anywhere:: Not provided
First Use In Commerce: Not provided
General Information
Word mark: TIME-POINT: TANESPIMYCIN IN MYELOMA EVALUATION: PERFORMANCE OF HSP 90 INHIBITOR AS INITIAL THERAPY
Status/Status Date:
ABANDONED - NO STATEMENT OF USE FILED
9/10/2012
Serial Number: 77795574
Filing Date: 8/3/2009
Registration Number: NOT AVAILABLE
Registration Date: NOT AVAILABLE
Goods and Services: Medical and scientific research, namely, conducting clinical trials and clinical studies relating to pharmaceutical preparations for human use
Mark Description: NOT AVAILABLE
Type Of Mark: Service Mark
Published For Opposition Date: 6/15/2010
Last Applicant/Owner:
Bristol-Myers Squibb Company
New York, NY 10154
Mark Drawing Code: Standard Character Mark
Design Search:
(NO DATA)
Register Type: Principal
Disclaimer: ("TANESPIMYCIN IN MYELOMA EVALUATION: PERFORMANCE OF HSP 90 INHIBITOR AS INITIAL THERAPY")
Correspondent:
Bristol-Myers Squibb Company
Trademark Department
345 Park Avenue
New York NY 10154
Current Status:
ABANDONED - NO STATEMENT OF USE FILED
9/10/2012
Correspondent Search:
Marilyn F. Kelly is a correspondent of TIME-POINT: TANESPIMYCIN IN MYELOMA EVALUATION: PERFORMANCE OF HSP 90 INHIBITOR AS INITIAL THERAPY trademark.
Current Overall Rating:
RatingRatingRatingRatingRating

(0 review)

As seen on